Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28738588 | 1.00 | TP53 (0.50) | TP53TSHRSLC7A5RNPEPCYP1A2 | |
| SCHEMBL21998212 | 1.00 | TP53 (0.50) | TP53TSHRSLC7A5RNPEPCYP1A2 | |
| SCHEMBL8583868 | 0.85 | TP53 (0.47) | TP53TSHRSLC7A5 | |
| SCHEMBL5675218 | 0.85 | TP53 (0.47) | TP53TSHRSLC7A5 | |
| SCHEMBL8583856 | 0.85 | TP53 (0.47) | TP53TSHRSLC7A5 | |
| SCHEMBL18211012 | 0.83 | TP53 (0.50) | TP53TSHRSLC7A5RNPEPCYP1A2 | |
| SCHEMBL1261744 | 0.83 | TP53 (0.50) | TP53TSHRSLC7A5RNPEPCYP1A2 | |
| SCHEMBL5549445 | 0.80 | — | — | |
| SCHEMBL791249 | 0.80 | — | — | |
| SCHEMBL2687210 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VECTIVBIO COMET AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-20230107216-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) | 2023-04-06 | — | — | US | disclosed |
| US-20230072313-A1 | CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) | 2023-03-09 | — | — | US | disclosed |
| CN-113727966-A | Panthenol derivatives and use thereof | 彗星医疗股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-113727986-A | Cyclic panthenol derivative and use thereof | 彗星医疗股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3887353-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | Comet Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3887381-A2 | CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | Comet Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020113209-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | COMET THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020113213-A2 | CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | COMET THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107216-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | VNN1, NQO1, VKORC1 | TP53 709/4885TSHR 3451/4885SLC7A5 539/4885 |
| US-20230072313-A1 | CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | VNN1, VKORC1, PANK3 | TP53 956/4885TSHR 3245/4885SLC7A5 1256/4885 |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VNN1, VKORC1, PANK3 | TP53 956/4885TSHR 3245/4885SLC7A5 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.